Peter Langmuir
Incyte (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Colorectal Cancer Treatments and Studies, Lymphoma Diagnosis and Treatment, Myeloproliferative Neoplasms: Diagnosis and Treatment
Most-Cited Works
- → Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial(2011)1,527 cited
- → Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question(2001)518 cited
- → Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease(2021)466 cited
- → Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial(2010)417 cited
- → Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer(2011)296 cited
- → Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial(2011)289 cited
- → Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses(2017)289 cited
- → Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)(2012)231 cited
- → Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20(2007)196 cited
- → Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial(2014)192 cited